Ovarian Cancer

Medically integrated dispensing models enhance oral oncology drug education and improve compliance and patient monitoring. Read More ›

New model aims to ease transition from fee-for-service to value-based cancer care delivery using an oncology medical home framework and performance-based reimbursement that includes monthly care management payments. Read More ›

Incident cases of ovarian cancer differed little between ever users and never users of powder with no dose-response relationship. Read More ›

Patients and healthcare providers should be aware of the toxicities that may occur with the use of PARP inhibitors so that they can manage them appropriately. Read More ›

Although federal reform efforts are likely to stall in the Senate, legislation prohibiting gag clauses, claw backs, and price spreading are being passed at the state level. Read More ›

The use of combination therapies in the first- and second-line settings for advanced ovarian cancer has the potential to improve patient outcomes. Read More ›

Although performance category weightings remain unchanged from 2019, the Centers for Medicare & Medicaid Services has raised the bar for participating providers by increasing the performance threshold from 30 to 45 points in 2020. Read More ›

There are important changes to beneficiaries’ Medicare Part D prescription drug coverage for 2020. These changes will affect many patients’ out-of-pocket spending for anticancer drugs, including poly (ADP-ribose) polymerase inhibitors. Read More ›

A bipartisan bill designed to remove disparity in pricing between intravenously administered drugs and orally administered drugs for patients with cancer was passed in the House in March 2019 but awaits action in the Senate. Read More ›

CMS approves changes allowing limited utilization management in protected classes of drugs. However, other proposed changes that would have further eroded patient access were not implemented. Read More ›